Novel Treatment Approaches for SCLC and Future Perspectives
A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.
Dr Fonkoua on Alternatives to Platinum Chemotherapy in Cancer Care
August 9th 2023Lionel A. Kankeu Fonkoua, MD, discusses challenges arising from the ongoing shortage of platinum chemotherapy in the United States and suggests potential alternatives to cisplatin that may benefit patients with cancer during this shortage.
Collaboration Is Needed to Address Existing Disparities in Cancer Clinical Trials
Lionel Kankeu Fonkoua, MD, discusses the need for diverse representation across cancer clinical trials and research, emphasizes some of the disparities in enrollment criteria for these research efforts, and details some of the planned and ongoing initiatives at the Mayo Clinic that seek to facilitate change in the field.
2L Dosing Considerations and Management Strategies for SCLC
Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.
LAGOON and IMFORTE Trials: Data Updates and Expert Insights
A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.
Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy
A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.
Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond
Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.
Examining the Promise of Multicancer Early Detection Tests: Looking to the Future
July 26th 2023In this seventh episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss the data that are still needed to inform optimal utilization of multicancer early detection tests and their potential cost effectiveness.
Birtamimab Pushes the Needle in AL Amyloidosis
July 26th 2023Findings from an analysis of treatment patterns for patients with systemic amyloid light chain amyloidosis have demonstrated that several unmet needs exist, including timely diagnosis and limited survival outcomes for patients with advanced disease.
Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care
Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
Real World Data for Combination Strategies With Chemotherapy and Immunotherapy in ES-SCLC
Faculty discuss real world data for treatment approaches using chemotherapy in combination with immunotherapy in extensive-stage small-cell lung cancer.
Patient Scenario 2: 1L Management of ES-SCLC Positive for Synaptophysin With a Ki-67 Score of 90%
Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.
Examining the Promise of Multicancer Early Detection Tests: Takeaways From the ECLIPSE Trial
July 19th 2023In this sixth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss important takeaways from the ECLIPSE study (NCT04136002), which evaluated a cell-free DNA blood-based test for colorectal cancer in an average-risk population.
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd
Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib
A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.
ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC
Faculty discuss potential treatment approaches for limited stage small-cell lung cancer currently under investigation in the ADRIATIC and other ongoing trials.
Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC
Panel experts discuss strategies aimed at preventing and managing potential adverse events with first-line combination therapy approaches in extensive stage small-cell lung cancer.
Examining the Promise of Multicancer Early Detection Tests: Lessons Learned From PATHFINDER
July 12th 2023In this fifth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, walk through the key lessons learned from the prospective, multicenter PATHINDER study (NCT04241796), which evaluated a multicancer early detection test developed by GRAIL.
Assessing HER2 Expression in Metastatic Colorectal Cancer
Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.
Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer
Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.